EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Development of Risperidone PLGA Microspheres

Susan D'Souza, Jabar A Faraj, Stefano Giovagnoli, Patrick P Deluca

Journal of Drug Delivery · 28.01.2014 · 2014 · 1-11

DOI: 10.1155/2014/620464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Drug Delivery, erschienen am 28.01.2014. Verfasst von Susan D'Souza und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sunovion Pharmaceuticals Inc., Marlborough, MA 01752, USA. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Oakwood Labs, Oakwood, OH, Graduate School, University of Kentucky, Lexington, KY.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to design and evaluate biodegradable PLGA microspheres for sustained delivery of Risperidone, with an eventual goal of avoiding combination therapy for the treatment of schizophrenia. Two PLGA copolymers (50 : 50 and 75 : 25) were used to prepare four microsphere formulations of Risperidone. The microspheres were characterized by several in vitro techniques. In vivo studies in male Sprague-Dawley rats at 20 and 40 mg/kg doses revealed that all formulations exhibited an initial burst followed by sustained release of the active moiety. Additionally, formulations prepared with 50 : 50 PLGA had a shorter duration of action and lower cumulative AUC levels than the 75 : 25 PLGA microspheres. A simulation of multiple dosing at weekly or 15-day regimen revealed pulsatile behavior for all formulations with steady state being achieved by the second dose. Overall, the clinical use of Formulations A, B, C, or D will eliminate the need for combination oral therapy and reduce time to achieve steady state, with a smaller washout period upon cessation of therapy. Results of this study prove the suitability of using PLGA copolymers of varying composition and molecular weight to develop sustained release formulations that can tailor in vivo behavior and enhance pharmacological effectiveness of the drug.

Autor:innen und Institutionen

  • Sunovion Pharmaceuticals Inc., Marlborough, MA 01752, USA.
  • Fresenius Kabi USA, Skokie, IL 60077, USA.
  • Department of Chemistry and Technology of Drugs, Università degli Studi di Perugia, Via del Liceo 1, 06123 Perugia, Italy.
  • University of Kentucky College of Pharmacy, Lexington, KY 40536, USA.

Förderung

  • Oakwood Labs, Oakwood, OH
  • Graduate School, University of Kentucky, Lexington, KY

Zitieren

APA

D'Souza, S., Faraj, J. A., Giovagnoli, S., & Deluca, P. P. (2014). Development of Risperidone PLGA Microspheres. Journal of Drug Delivery, 2014, 1-11. https://doi.org/10.1155/2014/620464

Vancouver

D'Souza S, Faraj JA, Giovagnoli S, Deluca PP. Development of Risperidone PLGA Microspheres. Journal of Drug Delivery. 2014;2014:1-11. doi:10.1155/2014/620464

BibTeX
@article{DSouza2014,
  author = {D'Souza, Susan and Faraj, Jabar A and Giovagnoli, Stefano and Deluca, Patrick P},
  title = {Development of Risperidone PLGA Microspheres},
  journal = {Journal of Drug Delivery},
  year = {2014},
  volume = {2014},
  pages = {1--11},
  doi = {10.1155/2014/620464}
}
Kostenlos starten →